Studies have shown that chemokine receptors CCR-2 and CX3CR1 regulate skin fibrosis in cytokine-induced systemic sclerosis mouse models, suggesting that blocking C-C motif chemokine ligand (CCL-24) or CCL-2 to inhibit monocyte recruitment may be an attractive new therapy to limit SSc fibrosis manifestations (104). This evidence concerns the gene CCL2 and systemic sclerosis.